Role of cortisol hypersecretion in the pathogenesis of osteoporosis;Attuali conoscenze sulla patogenesi dell'osteoporosi: Il ruolo dell'increzione di cortisolo

Recenti Progressi in Medicina

Volumn 99, Issue 6, 2008, Pages 309-313

  Chiodini, Iacopo ^a,c   Scillitani, Alfredo ^b  

^a IRCCS   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Adrenal adenomas; Hypercortisolism; Osteoporosis; Vertebral fractures

Indexed keywords

ALENDRONIC ACID; GLUCOCORTICOID; HYDROCORTISONE;

ADRENAL CORTEX ADENOMA; BONE DENSITY; BONE MASS; CALCIUM ABSORPTION; CLINICAL FEATURE; CONVALESCENCE; CUSHING SYNDROME; FRACTURE; FRAGILITY FRACTURE; HUMAN; HYDROCORTISONE RELEASE; HYPERCALCIURIA; HYPERCORTISOLISM; HYPOGONADISM; OSTEOLYSIS; OSTEOPOROSIS; OUTPATIENT; PREVALENCE; REVIEW;

ADRENOCORTICAL HYPERFUNCTION; BONE DENSITY; CUSHING SYNDROME; EVIDENCE-BASED MEDICINE; FRACTURES, SPONTANEOUS; HUMANS; OSTEOPOROSIS;

EID: 46449102366     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Canalis E. Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin endocrinol Metab 1996; 81:3441-7.
2. Shaker JL, Lukert BP. Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin North Am 2005; 34:341-56.
3. Canalis E, Bilezikian JP, Angeli A, Giustina A. Perspectives on glucocorticoid induced osteoporosis Bone 2004; 34:593-8.
4. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid induced osteoporosis. Calcif Tissue Int 2006, 79:129-37.
5. Mancini T, Doga M, Mazziotti G, Giustina A. Cushing's syndrome and bone. Pituitary 2004, 7: 243-6.
6. Canalis E, Delany AM. Mechanism of glucocorticoid action in bone. Ann N Y Acad Sci 2002; 966: 73-81.
7. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88: 593-602.
8. Rubin ME, Bilezikian JP. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 2002; 87: 4033-41.
9. Cooper MS, Rabbitt EH, Goddard PE, et al. Osteoblastic 11b-hydroysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 2002; 17: 979-86.
10. Huizenga Na, Koper JW, De Lange P, et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998; 83: 144-51.
11. Hermus AR, Smals AG, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 1995; 80: 2859-65.
12. Osella G, Terzolo M, Reimondo G, et al. Serum markers of bone and collagen turnover in patients with Cushing's syndrome and in subjects with adrenal incidentalomas. J Clin Endocrinol Metab 1997; 82: 3303-07.
13. Chiodini I, Carnevale V, Torlontano M, et al. Alterations of bone turnover and mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing's syndrome. J Clin Endocrinol Metab 1998; 83: 1863-7.
14. Kristo C, Jemtland R, Ueland R, Godang K, Bollerslev J. Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. Eur J Endocrinol 2006; 154: 109-18.
15. Lian JB. Bone formation: osteoblast lineare cells, growth factors, matrix proteins and the mineralization process. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. Philadelphia: Lippincott Williams & Wilkins 1999.
16. Di Somma C, Colao A, Pivonello R, et al. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Clin Endocrinol 1998; 48:655-62.
17. Tauchmanovà L, Rossi R, Nuzzo V, et al. Bone loss determined by quantitative ultrasonometry correlates inversely with disease activity in patients with endogenous glucocorticoid excess due to adrenal mass. Eur J Endocrinol 2001; 145: 241-7.
18. Di Somma C, Pivonello R, Loche S et al. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol 2003; 58: 302-8.
19. Tauchmanovà L, Pivonello R, Di Somma C, et al. Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 2006; 91: 1779-84.
20. Genant HK, Jiang J. Advanced imaging assessment of bone quality. Ann N Y Acad Sci 2006; 1068: 410-28.
21. Chiodini I, Torlontano M, Carnevale V, Trischitta V, Scillitani A. Skeletal involvement in adults patients with endogenous hypercortisolism, J Endocrinol Invest 2008 (in corso di stampa).
22. Vestergaard P, Lindholm J, Jørgensen JOL, et al. Increased risk of osteoporotic fractures in patients with Cushing's sindrome. Eur J Endocrinol 2002; 164: 51-6.
23. Reincke M. Subclinical Cushing's Syndrome. Endocrinol Metab Clin North Am 2000; 29: 47-56.
24. Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous sublinical hypercortisolism: diagnostic uncertainties and clinical implications. J Endocrinol Invest 2006; 29: 471-82.
25. Devogelaer JP. Incidentaloma, glucocorticoid excess and low bone mineral density: a coincidence? Eur J Endocrinol 2001; 145: 237-9.
26. Torlontano M, Chiodini I, Pileri M, et al. Altered bone mass and turnover in female patients with adrenal incidentaloma: the effect of subclinical hypercortisolism. J Clin Endocrinol Metab 1999; 84: 2381-5.
27. Chiodini I, Torlontano M, Carnevale V, et al. Bone loss rate in adrenal incidentalomas: a longitudinal study. J Clin Endocrinol Metab 2001; 86: 5337-41.
28. Chiodini I, Tauchmanovà L, Torlontano M, et al. Bone involvement in eugonadal male patients with adrenal incidentaloma and subclinical hypercortisolism. J Clin Endocrinol Metab 2002; 87:5491-4.
29. Hadjidakis D, Tsagarakis S, Roboti C. Does subclinical hypercocrtiolism adversely affect the bone mineral density of patients with adrenal incidentalomas? Clin Endocrinol 2003; 58: 72-7.
30. Chiodini I, Guglielmi G, Battista C. Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effect of subclinical hypercortisolism and gonadal status. J Clin Endocrinol Metab 2004; 89: 2237-41.
31. Rossi R, Tauchmanovà L, Luciano A, et al. Subclinical Cushing's sindrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 2000; 85: 1440-8.
32. Osella G, Reimondo G, Peretti P, et al. The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis. J Clin Endocrinol Metab 2001; 86: 604-7.
33. Kanine V, Fournier JJ, Requeda E, Luton JP, Simon F, Crouzet J. Osteoporotic fractures at presentation of Cushing's disease: two case reports and literature review. Joint Bone Spine 2000; 67: 341-5.
34. Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002; 87: 4431-7.
35. Kann P, Laudes M, Piepkorn B, Heintz A, Beyer J. Suppressed levels of serum cortisol following high-dose oral dexamethasone administration differ between healthy postmenopausal females and patients with established primary vertebral osteoporosis. Clin Rheumatol 2001; 20: 25-9.
36. Chiodini I, Mascia ML, Carnevale V, Muscarella S, Minisola S, Oldani M, et al. Prevalence of subclinical hypercortisolism in subjects screened for osteoporosis. Ann Int Med 2008; 147: 541-48.